Hy-Tech vs Symbiotec vs Skyways IPO: Best GMP?

 

Hy-Tech Engineers vs Symbiotec vs Skyways Air IPO GMP: Which Could Deliver the Highest Listing Gain?

Three mainboard IPOs — Hy-Tech Engineers, Symbiotec Pharmalab and Skyways Air Services — are competing for investor attention on the final day of bidding on August 27, 2026. All three issues opened on August 24, but the grey-market signals and subscription levels are telling very different stories.

Based on the latest available Day 4 data, Hy-Tech Engineers is clearly leading on implied listing gains, with a GMP of ₹44 against an upper issue price of ₹53. That points to an estimated listing price of ₹97, or an implied gain of about 83%. Skyways Air Services follows with an implied gain of about 30%, while Symbiotec Pharmalab is at roughly 29%.

But GMP is only one part of the IPO decision. For investors deciding between the three, valuation, financial performance, issue structure, sector outlook and subscription demand also deserve attention.

Hy-Tech Engineers vs Symbiotec vs Skyways: GMP Comparison

IPO	Upper Price	Latest GMP*	Implied Listing Price	Implied Gain
Hy-Tech Engineers	₹53	₹44	₹97	83.02%
Skyways Air Services	₹138	₹42	₹180	30.43%
Symbiotec Pharmalab	₹988	₹285	₹1,273	28.85%

*GMP is unofficial and can change before listing.

The comparison is important because the absolute GMP numbers cannot be compared directly. Symbiotec has a GMP of ₹285, much higher than Hy-Tech's ₹44, but its IPO price is also ₹988. What matters for a listing-gain comparison is the percentage premium relative to the IPO price.

On that basis, Hy-Tech Engineers is comfortably ahead.

1. Hy-Tech Engineers IPO: Clear Leader on GMP

Hy-Tech Engineers has emerged as the strongest listing-gain candidate among the three based on current grey-market indications.

The company has fixed its IPO price band at ₹50–₹53 per share, with a lot size of 283 shares. At the upper price, one retail lot requires ₹14,999. The ₹135.73 crore issue consists of a ₹60 crore fresh issue and a ₹75.73 crore offer for sale.

The latest GMP of ₹44 suggests an implied listing price of ₹97. That works out to approximately 83.02% above the upper IPO price.

Investor demand is also exceptionally strong. By 10:30 a.m. on August 27, the issue had been subscribed 67.42 times, according to the latest available data from NDTV Profit.

What makes Hy-Tech interesting?

Hy-Tech Engineers operates in industrial engineering and manufactures iron and steel products, including hydraulic fittings and industrial components.

The combination of strong subscription, a high GMP and a relatively small issue has made it the standout IPO for investors focused primarily on potential listing gains.

However, that also means expectations are high. If grey-market sentiment weakens before listing, the implied premium could fall sharply.

2. Skyways Air Services: Strong Second on Listing Potential

Skyways Air Services currently ranks second among the three based on implied GMP-based returns.

Its IPO has a price band of ₹131–₹138 per share, with a lot size of 100 shares. A retail investor needs ₹13,800 at the upper price band for one lot. The issue size is ₹582.8 crore.

The latest GMP of ₹42 implies a potential listing price of around ₹180, representing an estimated 30.43% premium over the upper issue price.

Subscription demand has also been healthy. At around 10:25 a.m. on August 27, the issue had received more than seven times subscription, with NII demand at 12.83 times and retail subscription at 8.17 times.

Skyways operates in logistics and freight forwarding, including air freight, ocean freight, road transportation, warehousing and customs-related services.

Its financial performance also provides some support to the IPO story. The company reported FY2026 profit of ₹63.5 crore, up 32% year-on-year, while revenue increased 25.1% to ₹2,812.9 crore.

That makes Skyways an interesting option for investors who want to look beyond GMP and examine an operating business with meaningful scale.

3. Symbiotec Pharmalab: Lower GMP, Different Investment Story

Symbiotec Pharmalab is the largest issue among the three, raising ₹1,757 crore.

The IPO price band is ₹938–₹988, and the minimum lot is 15 shares, requiring ₹14,820 at the upper price band. The issue includes a ₹150 crore fresh issue and a much larger ₹1,607 crore OFS component.

Its latest GMP of ₹285 indicates an implied listing price of approximately ₹1,273, translating into a 28.85% potential listing gain if the grey-market premium remains unchanged.

The IPO had been subscribed 5.31 times as of the latest reported Day 4 data, with the NII category at 12.18 times and retail at 5.05 times.

Symbiotec operates in specialised pharmaceutical manufacturing, including active pharmaceutical ingredients (APIs). It has exposure to steroidal and hormone-related APIs, CDMO activities and specialised pharmaceutical products.

The company also plans to use ₹112.5 crore of IPO proceeds for repayment or prepayment of selected borrowings.

Which IPO Has the Highest Potential Listing Gain?

If the question is purely about the current GMP-based listing premium, the ranking is straightforward:

1. Hy-Tech Engineers — 83.02%

2. Skyways Air Services — 30.43%

3. Symbiotec Pharmalab — 28.85%

Hy-Tech's lead is substantial. Its estimated premium is more than twice the implied gain of the other two IPOs.

There is another interesting comparison when looking at the potential gain per minimum retail lot based on the latest GMP.

For Hy-Tech Engineers, ₹44 multiplied by 283 shares gives an implied gain of around ₹12,452.

For Symbiotec, ₹285 multiplied by 15 shares gives approximately ₹4,275.

For Skyways, ₹42 multiplied by 100 shares gives approximately ₹4,200.

These are only theoretical GMP-based figures, not guaranteed profits.

GMP vs Fundamentals: What Should Investors Focus On?

This is where the three IPOs become harder to compare.

Hy-Tech Engineers currently dominates on short-term market sentiment and subscription demand.

Skyways Air Services combines a positive GMP with strong recent revenue and profit growth in the logistics sector. Its IPO proceeds also include debt repayment and working-capital requirements.

Symbiotec Pharmalab offers exposure to specialised pharmaceutical manufacturing and APIs. Its GMP is lower than the other two, but its business has a different long-term growth profile. At the upper price band, its FY2026 P/E was around 52 times, highlighting the importance of valuation for long-term investors.

Therefore, the IPO with the highest potential listing gain does not automatically become the best long-term investment.

The Biggest Risk: Chasing GMP

Investors should be particularly careful with the current GMP figures.

Grey-market premiums are unofficial and speculative. They are not determined by NSE or BSE and can change significantly before the shares actually begin trading.

For example, Hy-Tech's GMP had been reported at ₹40 at the end of Day 3, implying a 75.47% premium. By the morning of Day 4, it had moved to ₹44, taking the implied premium above 83%.

That movement itself demonstrates why GMP should not be treated as a fixed listing forecast.

An IPO can also list below its grey-market indication if broader market sentiment deteriorates or demand changes.

Final Verdict: Which IPO Looks Strongest for Listing Gains?

If the objective is only to identify the IPO currently showing the highest potential listing gain, Hy-Tech Engineers is the clear leader.

Its ₹44 GMP against a ₹53 upper issue price implies an 83.02% premium, while its subscription level has also far exceeded those of Symbiotec and Skyways.

Skyways Air Services comes second with an implied 30.43% premium, supported by strong subscription and solid FY2026 financial growth. Symbiotec Pharmalab is third on GMP at around 28.85%, but offers a differentiated pharmaceutical manufacturing and API business.

For investors, however, the right choice depends on the objective. Listing-gain seekers may find Hy-Tech the most attractive based on current GMP signals, while long-term investors should compare valuations, profitability, debt, industry prospects and business quality before choosing any of the three.

The next major milestones are the August 28 allotment and the expected September 1 listing for all three issues.

Follow our blog for more IPO comparisons, GMP updates, stock-market news and investor-focused analysis.

This article is for informational and educational purposes only and should not be considered investment advice